The health insurance expands its coverage to Hoya MiYosmart glass

The ongoing advancements in optical technologies within the field of visual health mark a significant step forward with the extended coverage by Health Insurance of the Hoya MiYosmart lenses. This innovation in the treatment of childhood myopia is now part of a context of enhanced prevention in response to the concerning rise in cases of progressive myopia among children. In 2025, specific coverage by Social Security and complementary health insurance positions this lens as a key tool to reduce the development of high myopia, a major public health issue. It is no longer just about correcting vision but also about directly acting on the progression of myopia, which substantially changes the dynamics of visual prevention. The adoption of an LPP (List of Products and Services) code under the brand name MiYosmart officially recognizes this innovative technology, facilitating access for children aged 5 to 16 years and contributing to better overall visual protection.

The decision to include this type of lens in the list of equipment benefiting from specific reimbursement results from three years of intense negotiations between the manufacturer Hoya, government institutions, supplementary organizations (Ocam), and optometry professionals. This approach aims to address a dual challenge: limiting the health consequences associated with the rapid progression of myopia and facilitating economic access to these dual-function correcting and slowing lenses. The collective awareness of the risks related to severe myopia, including increased risk of serious ocular complications in adulthood, played a decisive role in adopting this measure.

The specific coverage provided by Health Insurance up to 44.28 euros on a total cost set at 147.60 euros per lens mimics a desire to reduce the out-of-pocket expense for families, which will be supplemented by responsible contracts from mutual insurance companies. Social Security thus aligns with a healthcare efficiency dynamic, supporting an innovative solution recognized and validated by the High Authority of Health (HAS). This advancement also marks a turning point in the use of lenses in optics, emphasizing strict eligibility criteria focused on at-risk profiles—children with high or rapidly progressing myopia, with rigorous monitoring and appropriate renewal.

Innovative features of the Hoya MiYosmart lens for slowing progressive myopia

The MiYosmart lens from Hoya introduces a novel concept in pediatric optics, combining visual correction with action to slow the progression of myopia. This technical and functional specificity sets this product apart from traditional single-vision lenses. Its design is based on a patented technology called D.I.M.S. (Defocus Incorporated Multiple Segments), allowing the creation of a specific focal shift capable of stimulating the retina to slow exaggerated eye growth, the main cause of progressive myopia.

• 🛡️ Dual function : correction of myopia and slowing its progression.
• 🔬 D.I.M.S. technology : integrated multiple segments to induce controlled focal shift.
• 👁️ Designed for children : specifically tailored for 5 to 16-year-olds at risk of rapid progression.
• ⚙️ Patented optical structure : validated by clinical studies indicating a reduction in myopia progression between 30% and 60%.

This innovative structure represents a real breakthrough in pediatric visual protection. By effectively slowing down myopia, it plays a crucial role in preventing potential complications such as retinal detachment or macular degeneration, often associated with high myopia in adulthood. The MiYosmart lens, combining correction and prevention, thus offers significant health benefits.

🔑 Characteristic	⚙️ Description	📊 Clinical Impact
Dual function	Optical correction + slowing of myopia	Reduces progression by 30%-60%
D.I.M.S. technology	Multiple segments creating focal shift	Stimulates the retina to slow ocular growth
Target audience	Children aged 5 to 16 at risk of progression	Optimal management according to HAS criteria
Validation	Clinical studies and official recognition	Approved by Health Insurance and supplementary insurers

It should be noted that this technical innovation also involves an evolution in the roles of healthcare professionals in monitoring and prescribing, requiring regular control of the myopic development in patients to optimally adapt the renewal of equipment.

Coverage by Health Insurance: procedures and challenges for families

The specific reimbursement of the Hoya MiYosmart lens by Health Insurance is a significant step forward in access to myopia control solutions. From now on, Health Insurance contributes up to 44.28 euros on a recommended retail price of 147.60 euros including taxes per lens. This coverage results in a tangible reduction in out-of-pocket expenses for families, who can also benefit from support via their health insurance contracts, provided they have a responsible policy.

Among the conditions to benefit from this reimbursement, several criteria are essential:

• 📋 Mandatory prescription for the MiYosmart lens mentioning the LPP code 2236215 on the prescription.
• 👶 Patient’s age between 5 and 16 years.
• 📈 Confirmation of high myopia (≥ -6 diopters) or rapid progression (≥ -0.5 diopter per year) according to thresholds set by HAS.
• 🔄 First equipment or renewal for the relevant profile.

It should be noted that this coverage is strictly reserved for cases meeting the most severe clinical thresholds to optimize the use of public health resources. For other patients, especially those not meeting HAS criteria, alternative coverage is provided via a separate EDI exchange code, allowing access to the MiYosmart Open range. This measure aims to prevent the exclusion of myopic children who still require appropriate visual correction and can benefit from Hoya technology.

🔖 Criterion	✅ Condition	💡 Objective
Age	From 5 to 16 years	Target population for effective slowing
High myopia	≥ -6 diopters	High-risk patient
Rapidly progressive myopia	≥ -0.5 diopters/year	Monitoring and urgent management
LPP code	2236215 on prescription	Ensure specific management

This organization also facilitates coordination between ophthalmologists, orthoptists, and opticians, serving as an effective specialized eyewear pathway for targeted management. The goal is to achieve maximum visual protection through appropriate monitoring, combining innovative technologies with responsible reimbursement policies.

The health impact of MiYosmart lenses on the prevention of severe myopia

High or progressive myopia poses a major challenge to eye health worldwide. It is associated with an increased risk of serious eye diseases such as glaucoma, cataracts, or retinal detachment, which can lead to permanent vision loss. In this sense, the reimbursement measure for the Hoya MiYosmart lens reflects a targeted action to limit these risks by intervening early in the trajectory of childhood myopia.

Clinical data, validated by the High Authority of Health and ophthalmology scientific societies, point to a significant slowdown in myopia progression among children equipped with MiYosmart lenses. The average reduction observed ranges from 30% to 60%, representing a crucial benefit not only in terms of immediate quality of life but also in preventing future pathologies.

• 🩺 Risk reduction : decreased incidence of complications related to severe myopia.
• 👦👧 Target population : children aged 5 to 16 at high risk.
• 🔄 Regular monitoring : renewal of prescription based on myopia progression.
• 💸 Economic optimization : proactive prevention leading to savings on future costly care.

📈 Indicator	📉 Expected effect	💰 Cost impact
Myopia progression	Decreases by 30% to 60%	Reduces future surgical needs
Incidence of complications	Significant decrease	Fewer expenses related to serious pathologies
Quality of life	Notable improvement for young patients	Fewer major medical interventions

This policy aims to be an exemplary model of visual protection and integrated prevention, placing the MiYosmart lens as a key player in public health strategy for ophthalmic care.

The integration of MiYosmart lenses into the reimbursement policy: role of supplementary health insurance

Beyond the participation of Health Insurance, supplementary health insurers play an essential role in covering the full cost of Hoya MiYosmart lenses. These contracts, often called “responsible,” cover the remaining share that can exceed 100 euros per lens, thus considerably reducing the out-of-pocket expense.

This coordinated approach aims to :

• 💼 Ensure equitable access to innovative technologies among families, regardless of income.
• 🏥 Promote a preventive eye health policy, strengthening actions initiated by Social Security.
• ⚖️ Avoid the risk of exceeding budgets, by providing a secure financial framework for consumers.
• 🔗 Facilitate coordination between care providers and optical health coverage actors.

🎯 Objective	📌 Description	🤝 Key partner
Accessibility	Additional coverage of out-of-pocket costs	Mutual insurance and complementary insurers
Prevention	Strengthening myopia prevention actions	Responsible contracts
Financial balance	Reducing expenditure related to lens costs	Healthcare professionals and insurers
Coordination	Medical follow-up and integrated coverage	Ophthalmologists, opticians, insurers

This organization also underscores that coverage by supplementary health insurance is contingent upon enrollment in a responsible contract, highlighting the importance of informed family choices to benefit from optimal coverage. This model ensures an effective eyewear pathway in the fight against progressive myopia, strengthening efforts in visual health.

Impact on the optical market and the visual health sector

The official recognition of partial reimbursement for the MiYosmart lens profoundly alters the dynamics of the optical market. Hoya benefits from strong institutional recognition, allowing it to establish its position in the innovative and therapeutic segment of spectacle lenses, which had been underappreciated in the nomenclature until now. This lens becomes an emblematic product, marking a shift towards a more preventive and personalized optics approach.

This change has notable repercussions:

• 📊 Market stimulation through novelty and increased coverage.
• 🏭 Strategic orientations within lens manufacturers towards similar innovations.
• 🛠️ Enhanced offerings in optical retail outlets and laboratories.
• 📈 Expected growth of devices featuring slowing correction lenses.

🛒 Element	📈 Observed effect	🏆 Direct consequence
Official recognition	Specific reimbursement by Health Insurance	Increased demand
Technological innovation	Enhancement of R&D	Development of similar products
Optical retail points	Enriched and specialized offerings	Better customer coverage
Equipment market	Growth of the myopia slowing segment	Consolidation of the visual health sector

This evolution also enhances visibility of issues related to childhood eye health, raising awareness among families and healthcare professionals about the importance of adopting suitable solutions from an early age.

Education and awareness about progressive myopia and visual protection

The significant increase in myopia among children highlights the urgent need for collective awareness. The integration of the MiYosmart lens into the reimbursement system necessarily involves an active policy of information and education aimed at families and optical healthcare professionals.

Awareness campaigns emphasize several key areas:

• 📚 Clear information : about the risks of high myopia and the benefits of slowing lenses.
• 🔍 Early diagnosis : importance of regular assessments by specialists.
• 👓 Assistance in choosing : the role of opticians and ophthalmologists in recommending the appropriate correction.
• 🧒 Family support : guidance and advice to ensure consistent wear.

This educational effort aims to create an effective eyewear support system not only technically but also behaviorally, thus facilitating the long-term adoption of Hoya MiYosmart solutions in the fight against the progression of childhood myopia.

🎓 Educational goal	📌 Recommended action	📅 Timeline
Family information	Educational materials and media campaigns	Ongoing throughout the year
Diagnosis	Minimum yearly visual assessment	Annually during consultations
Guidance	Targeted MiYosmart prescriptions	According to myopia progression
Behavioral follow-up	Advice to parents/guardians	After each renewal

Future prospects for optical coverage and innovations by 2030

The current decision to expand Health Insurance coverage for the MiYosmart lens paves the way for a profound transformation in optometry practices. By 2030, several technological and organizational challenges are to be anticipated:

• 🔮 Development of new technologies aimed at the prevention and correction of evolving ametropias.
• 🤖 Integration of connected devices for real-time monitoring of myopia progression.
• 📊 Optimization of care pathways through better coordination between healthcare professionals and insurers.
• 🌍 Increased accessibility for all populations, including in less-covered areas.

The experience gained with Hoya MiYosmart will serve as the basis for this wave of innovations and corrective measures. It demonstrates the potential of an integrated and exemplary health action combining technological advances with appropriate reimbursement policies.

🚀 Domain	📈 Expected progress	🌟 Projected benefits
Optical technologies	Advanced multifunctional lenses	Improved correction and prevention
Connected devices	Real-time personalized monitoring	Early and adjusted intervention
Care pathways	Enhanced coordination	Efficiency and better quality
Accessibility	Expansion of geographical coverage	Guaranteed equality of access

Common questions about the coverage of the Hoya MiYosmart lens

Q1 : What is the specific regulation allowing reimbursement of the MiYosmart lens?
A: A decree published in the Official Journal assigns a brand name LPP code (2236215) to the MiYosmart lens, ensuring a specific coverage by Health Insurance, separate from standard single-vision lenses.

Q2 : What is the age range covered by MiYosmart lens coverage?
A: This coverage applies to children aged 5 to 16 years showing high myopia or rapid progression, according to thresholds set by HAS.

Q3 : How is the cost of the equipment shared between Health Insurance and supplementary insurers?
A: Health Insurance reimburses 44.28 euros per lens on a total cost of 147.60 euros including taxes. The remaining amount is covered, depending on the responsible contract, by the mutual insurance or the beneficiary’s health insurer.

Q4 : Is there coverage available for children not meeting HAS criteria?
A: Yes, through the MiYosmart Open device under a separate EDI code, coverage is possible for approximately 1.6 million children who do not meet the priority criteria.

Q5 : What is the expected impact of this reimbursement on visual health?
A: It represents a real health lever to slow myopia progression, reduce high myopia cases, and prevent severe complications, thus contributing to better quality of life in the long term.

For more details, it is recommended to consult specialized sources such as Santé Magazine, La Croix, or Hoya Vision Care to follow recent developments regarding this coverage.

Source: www.frequenceoptic.fr